CBIO · Crescent Biopharma Inc
United States · RS rating 40 · As of 2026-11-03
| Price | 13.06 USD |
|---|---|
| 1-day change | +1.2% |
| RS rating (overall / 1M / 3M / 12M) | 40 / 42 / 35 / 53 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 23 / 27 / 18 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -215.8% |
| Sales growth Q/Q | -90.4% |
| Distance from 52-week high | +51.6% |
| Market cap (USD) | $782.9M |